呼出气一氧化氮指导的哮喘管理与常规护理对围产期结局的影响
本研究为多中心随机对照试验,比较基于呼出气一氧化氮(FENO)指导的哮喘管理与常规护理对围产期结局的影响。结果显示两组在主要复合围产期不良结局(早产、小于胎龄儿、围产期死亡或新生儿住院)及母体哮喘急性发作方面均无显著差异。
要点
- FENO指导的哮喘管理未改善围产期复合不良结局(OR 1.21,95%CI 0.94-1.56)。
- 早产、小于胎龄儿、围产期死亡及新生儿住院等次要结局亦无显著差异。
- 需住院或急诊就诊的母体哮喘急性发作两组间无显著差异(OR 1.19,95%CI 0.69-2.05)。
核心结论
- 由护士或助产士在产前门诊实施的FENO指导哮喘药物治疗未改善围产期结局。
研究设计与样本
- 多中心、平行组、随机对照试验,在六个医院产前门诊开展。
- 比较FENO指导的哮喘管理(每6-12周根据呼出气一氧化氮和症状调整治疗)与常规护理(试验中不进行治疗调整)。
- 采用隐蔽随机分配,按研究中心和自报吸烟状态分层,结局评估和统计分析采用盲法,意向性治疗分析。
主要发现
- 主要复合围产期不良结局(早产、小于胎龄儿、围产期死亡或新生儿住院)发生率:对照组594例中152例(25.6%),干预组603例中177例(29.4%),OR 1.21(95%CI 0.94-1.56),p=0.15。
- 早产OR 1.14(95%CI 0.78-1.68)。
- 小于胎龄儿OR 1.06(95%CI 0.78-1.68)。
- 围产期死亡OR 3.62(95%CI 0.80-16.5)。
- 新生儿住院OR 1.24(95%CI 0.89-1.72)。
临床怎么用
- 在产前门诊由护士或助产士实施FENO指导的哮喘管理未显示围产期获益,不支持常规采用该策略改善围产期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Asthma exacerbations in pregnancy are associated with adverse perinatal outcomes. We aimed to determine whether fractional exhaled nitric oxide (F ENO)-based asthma management improves perinatal outcomes compared to usual care. METHODS: The Breathing for Life Trial was a multicentre, parallel-group, randomised controlled trial conducted in six hospital antenatal clinics, which compared asthma management guided by F ENO (adjustment of asthma treatment according to exhaled nitric oxide and symptoms each 6-12 weeks) to usual care (no treatment adjustment as part of the trial). The primary outcome was a composite of adverse perinatal events (preterm birth, small for gestational age (SGA), perinatal mortality or neonatal hospitalisation) assessed using hospital records. Secondary outcomes included maternal asthma exacerbations. Concealed random allocation, stratified by study site and self-reported smoking status was used, with blinded outcome assessment and statistical analysis (intention to treat). RESULTS: Pregnant women with current asthma were recruited; 599 to the control group (608 infants) and 601 to the intervention (615 infants). There were no significant group differences for the primary composite perinatal outcome (152 (25.6%) out of 594 control, 177 (29.4%) out of 603 intervention; OR 1.21, 95% CI 0.94-1.56; p=0.15), preterm birth (OR 1.14, 95% CI 0.78-1.68), SGA (OR 1.06, 95% CI 0.78-1.68), perinatal mortality (OR 3.62, 95% CI 0.80-16.5), neonatal hospitalisation (OR 1.24, 95% CI 0.89-1.72) or maternal asthma exacerbations requiring hospital admission or emergency department presentation (OR 1.19, 95% CI 0.69-2.05). CONCLUSION: F ENO-guided asthma pharmacotherapy delivered by a nurse or midwife in the antenatal clinic setting did not improve perinatal outcomes.
引用
- Murphy VE, Jensen ME, Holliday EG, et al. Effect of asthma management with exhaled nitric oxide versus usual care on perinatal outcomes. Eur Respir J. 2022. PMID: 35777773. doi:10.1183/13993003.00298-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。